低级别浆液性卵巢癌与浆液性交界性肿瘤之间的诊断漂移:一项基于人群的研究
该研究基于SEER数据库1988至2000年数据,比较775例低级别浆液性卵巢癌(LGSOC)与3937例浆液性交界性卵巢肿瘤(serous-BOT)的特征与结局。研究发现LGSOC数量下降25.9%,尤其I期疾病相对下降37.6%,而II-IV期相对下降21.1%;LGSOC的15年总生存率呈下降趋势(相对下降28.7%,P=0.056),serous-BOT则无此趋势。LGSOC与serous-BOT相比,全因死亡风险比从1988至2000年增加了68.9%(P<0.001)。结论提示LGSOC数量与生存下降可能源于诊断从LGSOC向serous-BOT的漂移。
要点
- LGSOC数量在1988至2000年间下降25.9%,I期相对下降37.6%,II-IV期相对下降21.1%。
- LGSOC的15年总生存率相对下降28.7%(P=0.056),serous-BOT相对增加2.5%(P=0.416)。
- LGSOC对比serous-BOT的全因死亡风险比在1988至2000年间增加68.9%(P<0.001)。
核心结论
- LGSOC数量与生存率随时间下降可能归因于诊断从LGSOC向serous-BOT的漂移。
- LGSOC与serous-BOT特征和结局不同,强调初始正确诊断的重要性。
- serous-BOT是否为LGSOC前驱病变尚需进一步研究。
研究设计与样本
- 基于SEER数据库1988至2000年的基于人群的回顾性研究。
- 纳入775例高分化浆液性卵巢癌(作为LGSOC替代)和3937例浆液性交界性卵巢肿瘤女性。
- 中位随访16.9年,比较趋势、人口学特征和结局。
主要发现
- 多因素分析中,LGSOC女性更可能年龄较大、为II-IV期疾病、手术时行子宫切除术,但较少为美国西部居民(均调整P<0.05)。
- 研究期间LGSOC数量下降25.9%,I期相对下降37.6%,II-IV期相对下降21.1%(均P<0.05)。
- LGSOC的15年总生存率相对下降28.7%(P=0.056),serous-BOT相对增加2.5%(P=0.416)。
- LGSOC对比serous-BOT的全因死亡风险比从1988至2000年增加68.9%(P<0.001)。
- LGSOC仍是总生存下降的独立预后因素(调整P<0.05)。
临床怎么用
- 临床应重视LGSOC与serous-BOT的鉴别诊断,避免诊断漂移影响治疗决策。
- 对LGSOC患者需认识到其独立不良预后,即使调整其他因素后总生存仍较差。
局限性
- 研究为回顾性设计,使用高分化浆液性卵巢癌作为LGSOC替代可能引入错分偏倚。
- 数据来源于SEER数据库1988至2000年,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine changes in the characteristics of low-grade serous ovarian cancer (LGSOC) and serous borderline ovarian tumor (serous-BOT) in a time-specific manner. METHODS: We conducted a population-based retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1988 to 2000. Trends, demographics, and outcomes of 775 women with well-differentiated serous ovarian cancer, used as a surrogate for LGSOC, were compared to 3937 women with serous-BOT. RESULTS: In the multivariable analysis, women with LGSOC were more likely to be older, have stage II-IV disease, and have undergone hysterectomy at surgery, but less likely to be a Western U.S. resident compared to those with serous-BOT (all, adjusted-P < 0.05). During the study period, the number of LGSOCs decreased by 25.9%, particularly stage I disease (37.6% relative decrease) compared to stage II-IV disease (21.1% relative decrease) (all, P < 0.05). With a median follow-up of 16.9 years, there was a decreasing trend in the 15-year overall survival rates among LGSOC (28.7% relative decrease, P = 0.056) but not in serous-BOT (2.5% relative increase, P = 0.416) as a whole cohort. The magnitude of hazard risk from all-cause death for women with LGSOC compared to those with serous-BOT increased by 68.9% from 1988 to 2000 (P < 0.001). LGSOC remained an independent prognostic factor for decreased overall survival compared to serous-BOT (adjusted-P < 0.05). CONCLUSION: Our study suggests that the decreasing number and survival of LGSOC over time may be due to a diagnosis-shift from LGSOC to serous-BOT. Given the distinct characteristics and outcomes of LGSOC compared to serous-BOT, our study endorses the importance of making the correct diagnosis upfront. Whether this diagnostic-shift supports a hypothesis that serous-BOT is a precursor lesion of LGSOC merits further investigation.
引用
- Matsuo K, Machida H, Grubbs BH, et al. Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecol Oncol. 2020. PMID: 31954535. doi:10.1016/j.ygyno.2019.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。